Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
J Viral Hepat. 2022 Dec;29(12):1127-1133. doi: 10.1111/jvh.13745. Epub 2022 Sep 14.
Hepatitis delta virus (HDV) infection is associated with accelerated progression of liver disease to cirrhosis. Shear wave elastography (SWE) is a non-invasive evaluation method of liver fibrosis. Its performance in accurately characterizing HDV fibrosis compared to other noninvasive markers remains unknown. We assessed the performance of SWE in patients with chronic HDV, Hepatitis B (HBV) and Hepatitis C (HCV) infection. Cirrhosis was determined by histology or clinical data. Area under receiver operator characteristics (AUROC) was used to assess diagnostic performance in identifying cirrhosis by SWE in comparison with Fibroscan® (VCTE) and serologic tests of fibrosis. 158 patients with chronic hepatitis (HDV:44%, HBV: 46% and HCV: 29%) were evaluated. Cirrhosis was diagnosed in 28 (17.7%) patients. Mean noninvasive fibrosis measurements for the HBV/HCV and HDV groups, respectively, were as follows: APRI: 0.73 ± 1.08 and 1.3 ± 1.38; FIB-4: 1.90 ± 2.24 and 2.33 ± 2.24; VCTE: 8.9 ± 6.7 kPa vs 10.4 ± 5.3 kPa; SWE: 1.5 ± 0.2 m/s and 1.6 ± 0.2 m/s. The performance of SWE in detecting HDV-induced cirrhosis (AUROC 0.84, 95% CI 0.71-0.97) was slightly lower than in HBV/HCV induced disease (AUROC 0.88, 95% CI 0.81-0.96). For HDV patients, the performance of SWE was comparable to VCTE and slightly better than APRI and FIB-4 especially in APRI and FIB-4 indeterminate zones. The overall less accurate performance of noninvasive markers in HDV in comparison with HBV and HCV may be a result of significant hepatic inflammation in HDV.
乙型肝炎 delta 病毒(HDV)感染与肝脏疾病向肝硬化的加速进展有关。剪切波弹性成像(SWE)是一种非侵入性的肝纤维化评估方法。其在准确描述 HDV 纤维化方面的性能与其他非侵入性标志物相比仍不清楚。我们评估了 SWE 在慢性 HDV、乙型肝炎(HBV)和丙型肝炎(HCV)感染患者中的表现。肝硬化通过组织学或临床数据确定。接受者操作特征曲线(AUROC)下面积用于评估 SWE 在识别肝硬化方面的诊断性能,与 Fibroscan®(VCTE)和纤维化的血清学检测相比。评估了 158 例慢性肝炎患者(HDV:44%,HBV:46%和 HCV:29%)。28 例(17.7%)患者诊断为肝硬化。HBV/HCV 和 HDV 组的平均非侵入性纤维化测量值分别为:APRI:0.73±1.08 和 1.3±1.38;FIB-4:1.90±2.24 和 2.33±2.24;VCTE:8.9±6.7 kPa 与 10.4±5.3 kPa;SWE:1.5±0.2 m/s 和 1.6±0.2 m/s。SWE 在检测 HDV 引起的肝硬化(AUROC 0.84,95%CI 0.71-0.97)方面的性能略低于 HBV/HCV 引起的疾病(AUROC 0.88,95%CI 0.81-0.96)。对于 HDV 患者,SWE 的性能与 VCTE 相当,在 APRI 和 FIB-4 的不确定区域略优于 APRI 和 FIB-4。与 HBV 和 HCV 相比,非侵入性标志物在 HDV 中的整体准确性较低可能是由于 HDV 中存在显著的肝脏炎症。